Simplify's Take
What believers are saying
- Janux ended Q2 2026 with $970.9 million cash, funding multiple clinical readouts.
- JANX013 dosed its first patient on September 14, 2026, widening prostate combinations.
- JANX011 healthy-volunteer data is due in 2026, giving a non-oncology catalyst soon.
What critics are saying
- JANX008 failed in April 2026, exposing weak data-to-program conversion across the pipeline.
- William Go exited as CMO in June 2026, creating clinical leadership disruption during expansion.
- If JANX007 and JANX013 underperform, Janux becomes a single-asset prostate bet by 2027.
What makes JANX unique
- JANX007, JANX014, and JANX013 create a PSMA franchise under one platform.
- Janux’s TRACTr design targets tumor-activated delivery, seeking outpatient dosing and lower systemic toxicity.
- Bristol Myers Squibb collaboration validated the platform, with a development candidate milestone in May 2026.
Help us improve and share your feedback! Did you find this helpful?